80 results
Page 2 of 4
8-K
EX-99.1
v6wr78i1zn6k4gwh
10 May 21
FibroGen Reports First Quarter 2021 Financial Results
4:07pm
8-K
EX-99.1
px5r7gxhrndpcz mb
6 Apr 21
Company Continues to be Confident in the Benefit / Risk Profile of Roxadustat
4:59pm
8-K
EX-99.1
4oghvdt 1oex8
1 Mar 21
FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results
4:06pm
8-K
tsi26t
1 Dec 20
Departure of Directors or Certain Officers
8:05am
8-K
EX-99.1
jyq7qsfhgn zy3vy
5 Nov 20
FibroGen Reports THIRD Quarter 2020 Financial Results
4:05pm
8-K
EX-99.1
zhi1j
6 Aug 20
FibroGen Announces New Appointments to its Board of Directors
4:06pm
8-K
EX-99.1
l9ati0c6n
2 Mar 20
FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results
4:06pm
8-K
EX-99.1
0rp1rnijpya
30 Jan 20
Astellas Submits Supplemental New Drug Application for Approval of
4:40pm
8-K
EX-99.1
1ytbd6drzy56dnc4o2u9
12 Nov 19
FibroGen Reports Third Quarter 2019 Financial Results
8:16am
8-K
EX-99.2
jglkkmku5bkmf166otj
12 Nov 19
FibroGen Reports Third Quarter 2019 Financial Results
8:16am
8-K
EX-99.1
htp7k
8 Nov 19
Regulation FD Disclosure
2:05pm
8-K
ge3tad hlsneuib
8 Nov 19
Regulation FD Disclosure
2:05pm
8-K
9fbwee0ha
8 Nov 19
FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease
2:00pm